Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Andy Smith is a Certified Financial Planner (CFP®), licensed ...
Vertex Pharmaceuticals’ CRISPR-based therapy made history as the first drug of its type, transforming care options for sickle ...
Live Science on MSN
Science history: Edwin Hubble uncovers the vastness of the universe with discovery of 'standard candle' — Oct. 5, 1923
On the night of Oct. 5, 1923, Edwin Hubble observed a strange star that flickered in intensity at regular intervals. The star ...
Fintel reports that on October 10, 2025, Morgan Stanley maintained coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 18.17% Upside ...
Zacks Investment Research on MSN
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Ian Smith, the former chief financial officer of Vertex Pharmaceuticals, has taken over as CEO of Stoke Therapeutics.
Vertex broke those barriers with Journavx, the first non-opioid prescription pain killer in more than two decades, earning ...
Learn what residual standard deviation is, how to calculate it in regression analysis, and why it's crucial for measuring predictability and goodness-of-fit in data modeling.
Every time James publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...
Vertex Pharmaceuticals has been a clear winner in the pharmaceutical sector. Over the past two decades, this powerhouse has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback